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doi:10.1016/j.pedneo.2012.01.008Objective: There has been very limited research on the clinical features of newborns exposed
to combined use of heroin, methadone, and amphetamine in the uterus. We describe a tech-
nique for the quantification of drug metabolites in neonatal hair samples.
Methods: In a tertiary neonatal care center in Taiwan, three neonates whose mothers self-
reported heroin abuse with methadone treatment during pregnancy were studied. Involuntary
exposure to amphetamine was not suspected before the births. To assess long-term illicit drug
exposure during pregnancy, a quantifying technique of gas chromatography/mass spectrom-
etry (GC/MS) for hair samples from neonates was developed to replace current methods for
urine and blood specimens.
Results: All three mothers were addicted to heroin and prescribed oral methadone treatment
during pregnancy. Two males and one female were born and then admitted to the neonatal
intensive care unit because of apparent neonatal abstinence syndrome (NAS) after birth. Addi-
tional hypertonicity and cerebral dysfunction were also diagnosed by electroencephalography
in one case. Supportive care was given to the neonates, unless special treatments were needed
in responding to tachypnea, fetal distress, or withdrawal symptoms. During follow-up periods
from 10 months to 15 months, the signs of NAS remained and delays in milestones ofof Pediatrics, Chung Shan Medical University Hospital, No. 110 Chien-Kuo N. Road, Sec. 1, Taichung
.-Y. Chen).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Clinical effects of poly illicit drug on neonates 113development were observed. Further follow-up on the infants’ neurobehavioral development
is necessary. Measurement results of neonates’ hair samples revealed high levels of metabo-
lites of heroin, methadone, and amphetamine, reflecting the amount of illicit drug exposure
2e3 months before delivery.
Conclusion: The current study suggested the possibility of polydrug exposure, which was previ-
ously unknown in pregnant women in Taiwan. Measurement of neonatal hair samples could
provide a basis for clinical evaluation and potential corresponding treatment.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
As suggested in the 2002/2003 US National Survey on Drug
Use and Health, the prevalence of suffering from at least
one substance abuse in a year was approximately 11%
among adults. In addition, 4.3% of pregnant women aged
15e44 years used illicit drugs, resulting in 172,934 births
complicated by maternal use of illicit drugs in the USA.1
Approximately seven per 1000 adults aged 15e54 years
were heroin dependent in Australia, the UK, and Europe.
Among them, around 80e90% females were of reproductive
age.2 The babies of mothers with opiate dependence during
pregnancy have increased risks of bloodborne virus infec-
tions, including hepatitis B, hepatitis C, and HIV.3 Thus,
substance abuse has been listed as one of the 10 high-
priority public health issues for the US population in
Healthy People 2010.4
Fetuses exposed to heroin in the uterus have a fluctu-
ating cycle of intoxication and withdrawal after birth.
Among the adverse effects of heroin, NAS is the most
devastating clinical finding, including the symptoms of
tremor, fever, seizure, inability to self-quiet, elevated
startle reflex, feeding difficulty, abnormal sleep patterns,
and diarrhea. Among neonates who are exposed to opiates
in the uterus, 60e90% experience some degree of NAS.5e8
Pregnancy complications following substance use decrease
development indicators, elevate central nervous system
and autonomic nervous system signs, and increase devel-
opmental and behavioral problems when the affected
babies are growing up. Polydrug use, defined by the use of
more than one non-prescribed licit or illicit substance
either concurrently or simultaneously, worsens the situa-
tion in clinical management.8,9
Methadone, an artificial opiate derivative, has been
clinically recommended for the treatment of heroin
dependency to pregnant women since the 1970s.5 Metha-
done maintenance treatment gives the benefits of better
birth outcomes of neonates, reduction of heroin use during
pregnancy, and improvement of overall maternal health,
although the side effects of reduced fetal activities, low-
ered birth weight, and prolonged NAS symptoms exist.7
Physical changes during pregnancy complicate the clinical
management protocol, and make it more challenging to
maintain effective plasma concentration but, in the mean
time, minimize the chance of NAS occurring.10 However,
debates on how to minimize added maternal methadone
dosage in order to sustain plasma concentration while
restricting its impact on mothers and neonates are
ongoing.5,6,10e14Since 2000, opiates (including heroin) have become the
top illicit type of drug abused in Taiwan, contributing 70.3%
of positive results in urine screening programs conducted by
mental health service providers in 2006.15 Nonetheless,
there is scarce research on the combined use of amphet-
amine and heroin during pregnancy to the health of
neonates.9 Most of the related studies were performed
separately in western countries.6,8,16e19 Consequently, for
better insight into the issue of polydrug use of amphet-
amine and heroin during pregnancy, there is a need for
research in various study settings. We thus report the
clinical courses of three neonatal cases whose mothers
confessed that they continued using heroin with methadone
replacement therapy during pregnancy, with no idea that
amphetamine was foisted until it was identified in the
neonate’s hair and urine after birth. The methodology of
quantifying these illicit drugs in infants’ urine and hair was
correspondingly developed and reported.
2. Methods
2.1. Study settings
At our tertiary neonatal care center, three pregnant women
under suspicion of illicit drug usage were referred from July
1, 2009 to June 30, 2010. They were found addicted to
heroin and probably amphetamine during outpatient visits
with in-depth interview and routine examinations during
pregnancy. Neonatal urine and hair samples were regularly
collected for toxicological exams at 1 day old and 14 days
after admission. For Case 2, additional urine and hair
samples were collected on the 7th day and 16th day after
admission. For Case 3, hair was additionally collected
after the first day of use of morphine sulfate, after 48
hours, and then 14 days after morphine sulfate was dis-
continued. The research protocol was approved by the
Ethics Committee of Chung Shan Medical University
Hospital before the recruitment of cases.
2.2. Measurement methods
Hair samples were bundled and cut as close as possible to
the scalp because this is the region of least variation in
growth rate, at sites behind the ears, and on the occipital
bone within an area of approximately 5 cm2. If it cannot be
collected by the standard protocol, the alternate site for
hair sampling area must be described. The proximal end of
the sample must be specified if it was longer than 4 cm. In
114 P.-H. Su et aladdition, sufficient amount of hair (50 mg for about 100
hairs) must be collected to allow primary testing, followed
by confirmation of the sample if necessary. The samples
should be put in separate paper bags for shipment at room
temperature.
The commonly abused drugs in Taiwan suggested by
Centers of Disease Control, Taiwan15 were then measured
by gas chromatography/mass spectrometry (GC/MS),
according to this modified method for which a simultaneous
GC/MS assay was developed and validated.20 Utilization of
this new technique made it possible to simultaneously
determine four classes of illegal drugs in human hair,
including amphetamines (amphetamine, AP; metham-
phetamine, MA; 3,4-methylene dioxyamphetamine, MDA;
3,4-methylene dioxymethamphetamine, MDMA; 3,4-
methylene dioxyethylamphetamine, MDEA), ketamine
(ketamine, K; norketamine, NK), methadone (methadone,
MTD; 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine,
EDDP), and opiates (morphine, MOR; codeine, COD; 6-
acetylmorphine, 6-AM). In brief, hair samples (10 mg)
were washed, cut, and incubated overnight at 25C in
methanol, then extracted by solid-phase extraction (SPE),
and derivatized using heptafluorobutyric acid anhydride
(HFBA) at 70C for 30 minutes. Finally, the derivatives were
analyzed by GC/MS in full-scan or selected-ion monitoring
(SIM) mode. GC/MS analyses were performed with an Agi-
lent 6890 series automatic injector and GC interfaced to an
Agilent 5973 MS operated in electron ionization (EI) mode
(Agilent Technologies, Wilmington, DE, USA). Separation
was achieved with a 30-m HP-5 MS capillary column (5%
phenyl methyl siloxane with 0.25 mm I.D and 0.25 mm film
thickness (Agilent Technologies, Palo Alto, CA, USA) and the
helium carrier gas flow rate was set at 1 mL/min.
3. Results
3.1. Clinical courses and treatments
All three case mothers self-reported as current heroin
users, receiving methadone therapy for 1 week to 4
months, at the respective ages of 38, 31, and 32 years old at
delivery for gravida 3 para 3, gravida 5 para 2 SA 1 AA2, and
gravida 5 para 1 AA4, separately. Details of their illicit drug
use history, clinical features, symptoms/signs, and treat-
ment outcomes are shown in Table 1. One subject self-
reported combined use of amphetamine (Case 2). Two
cases were heavy smokers of two to three packs a day
(Cases 1 and 2), but neither was an alcohol user. All
outcomes of prenatal laboratory tests for the cases were
within normal range. There were no incidences of toxo-
plasmosis, other infections (syphilis, varicella, mumps,
parvovirus, and HIV), rubella, cytomegalovirus, and herpes
simplex (TORCH), hepatitis B, or any other sexually-
transmitted infections, but one subject had chronic hepa-
titis C with symptoms of hyperbilirubinemia, elevated
glutamyl oxaloacetic transaminase and glutamyl pyruvic
transaminase levels, and an episode of fulminant hepatitis
during pregnancy (Case 2). Mild to medium cholecystitis
was also noted before delivery. In addition, mitral valve
prolapse and a depressive episode of bipolar affective
disorder were experienced, with a suicide attempt byjumping from a high building resulting in multiple fractures.
Case 1 reported that throughout the whole pregnancy
she was on inhaled corticosteroid therapy for asthma.
Particularly, besides a 4-year history of intravenous heroin
abuse, Case 3 had been diagnosed as having depression with
hallucinations about 9 years before, according to her
anamnesis. However, she did not take antidepressants
regularly. She claimed that she had received elective
termination of pregnancy four times during her first
marriage because of the concern of adverse effects from
antipsychotics. She had started oral methadone treatments
3 years before and had been on oral methadone 1 mL/day
for about 4 months preceding the delivery, but intravenous
heroin injection was still used 1 day prior to delivery.
Two males and one female were born at the gestational
ages of 35, 34, and 38 weeks, respectively, with labor pain
plus preterm premature ruptured of membrane (PPROM),
labor pain plus uterine contraction by vaginal delivery
(Cases 1 and 2), and via cesarean section due to breech
presentation (Case 3). Their Apgar scores at 1 min were 9,
6, and 6, respectively, and 10, 7, and 9 at 5 minutes,
respectively. Intrauterine growth restriction (IUGR) with
low birth weight was diagnosed in two of them. Ponderal
indexes21 of 2.02%, 2.72%, and 2.26%, respectively, were
identified. On the first day, all neonates were admitted into
the neonatal intensive care unit (NICU) for significant NAS,
including moderate tremors when undisturbed, high-
pitched crying, irritability, tachypnea, and poor feeding
with uncoordinated sucking. Only Case 3 had hypertonicity.
Serial brain ultrasound exams, electroencephalography,
and brainstem auditory evoked potentials were unremark-
able for all neonates, except that electroencephalography
of Case 3 showed cerebral dysfunction on the 3rd day, but
improved after treatment.
Following our protocol for treatment of neonates with
maternal heroin exposure in the NICU, each infant was
placed in a darkened incubator and the modified Finnegan
neonatal abstinence scoring system22 was applied every 4
hours. In Case 1, a condition of tachypnea with 70 respi-
rations/min developed on admittance, therefore nasal
continuous positive airway pressure was used for 2 days. In
spite of the long duration of maternal heroin addiction, no
consecutive scores higher than eight within three times
were obtained during the 2 weeks’ duration of observation.
Thus, the baby received supportive care without particular
medication intervention. For Case 2, umbilical cord twice
around the neck with moderate to heavy meconium stained
and cyanosis was found when labored. Fetal distress and
heroin withdrawal symptoms were noted. An oxygen hood
was used for the first 2 days. Also, no continuous Finnegan
neonatal abstinence scores >8 for three times were
observed within 2 weeks. Accordingly, only supportive care
was given. For Case 3, following the practical guidelines,14
drug treatment with phenobarbital proceeded in a loading
dose of 15 mg/kg and the remainder administered 6 mg/kg
from the first day of admission. Repeated scoring every
4 hours using the modified Finnegan neonatal abstinence
scoring system revealed 6e12, after treatment for 1 week.
Thus, morphine sulfate was combined with phenobarbital in
a dosage of 40 mg/kg every 4 hours. After 5 days of
combination treatment with phenobarbital and morphine
sulfate, his condition was stabilized. The score decreased
Figure 1 Gas chromatography/mass spectrometry-selected-
ion monitoring (GC/MS-SIM) chromatograms of hepta-
fluorobutyric acid anhydride (HFBA) derivatization of the
investigated drug, which spiked with 5 ng/mg. The X-axis is
intensity of quantification ions, and the Y-axis is the eluted
time of the investigated drugs. 1 Z amphetamine (AP); 2 Z
methamphetamine (MA); 3Z 3,4-methylene dioxyamphetamine
(MDA); 4 Z 3,4-methylene dioxymethamphetamine (MDMA);
5Z norketamine (NK); 6Z ketamine (K); 7Zmethadone (MTD);
8 Z 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP);
9 Z morphine (MOR); 10 Z codeine (COD); 11 Z 6-acetyl-
morphine (6-AM).
Table 1 Clinical courses, symptoms, signs, and treatment outcomes of the subjects.
Subject Item Case 1 Case 2 Case 3
Mother Illicit drug use history
Heroin
Methadone before delivery
Amphetamine
2 years
3 months
Denied
2 years
1 week
2 years
4 years
4 months
Denied
Newborn Gestational age (weeks) 35 34 38
IUGR þ þ 
C/S or NSD NSD NSD C/S
Perinatal event PPROM MAS 
Birth weight (kg) 2.100 (10th percentile) 2.016 (<10th percentile) 3.184 (10e25th percentile)
Body length (cm) 47 (25e50th percentile) 42 (25e50th percentile) 52 (75th percentile)
Head circumference (cm) 30.5 (10th percentile) 30 (10th percentile) 34.5 (25th percentile)
High pitched cry þ þ þ
Tremor þ þ þ
Excessive sucking þ þ þ
Tachypnea þ þ þ
Hypertonicity   þ
NASS <8 <8 >8
C/S Z cesarean section; IUGR Z intrauterine growth restriction, defined as having a birth weight which is more than two standard
deviations below the mean or less than 10th percentile of a population-specific birth weight versus gestational age plot;26 MAS Z me-
conium aspiration syndrome; NASS Z Neonatal Abstinence Scoring system; NSD Z normal spontaneous delivery; PPROM Z preterm
premature rupture of membrane.
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day of life. Morphine sulfate was gradually stopped,
reduced by 5 mg/kg per day during a period of 8 days and
withheld on the 22nd day after birth.
Case 1 has been followed for a period of 15 months. The
signs of high-pitched cry, frequent irritability, and poor
feeding leading to failure to thrive and developmental
retardation were still observed at 6 months. Currently, the
case has delays in developmental milestones, sitting alone
at 1 year old, and not able to walk alone yet. Case 2 has
been followed for 10 months. Her signs of high-pitched
cry, frequent irritability, and poor feeding leading to failure
to thrive continued in the follow-up period. She also
experiences delay in the developmental milestone for
rolling over alone at 9 months old. At discharge, Case 3 was
found with excessive sucking and loose stool. At present, he
has been followed up for 15 months, and delays in devel-
opmental milestones have been observed (sitting alone at
10 months old and not walking alone yet). Also, he mani-
fests inappropriate laughing. Prolonged follow-up was rec-
ommended for further assessments on his neurobehavioral
development.
3.2. Measurement outcomes
Urine specimens of the three neonates were first examined
by an enzyme immunoassay to identify opiates, amphet-
amines, MDMA, marijuana, and ketamine, on the 1st day
after birth. The positive specimens were tested by GC/MS
to determine the presence of the targeted analytes above
threshold concentrations. The results showed that none of
the samples revealed a positive finding in urine, except
Case 3, who was positive for morphine at a concentration of
308 ng/mL.All quantitative analyses of hair specimens were per-
formed with GC/MS in selected ion-monitoring mode with
20 ms of dwelling time for each ion (Figure 1). The GC/MS
SIM chromatogram of the investigated drugs (HFBA, MA-
HFBA, MOR-HFBA, MTD, EDDP, MOR-HFBA, COD-HFBA, and
6-AM-HFBA) after derivatization depicts pikes at 2.56 min,
3.06 min, 6.50 min, 7.13 min, 8.24 min, 8.42 min, and
8.83 min, respectively. Ions monitored in SIM mode were:
116 P.-H. Su et alm/z 254, 210, 118 for MA; m/z 258, 123 for MA-d5; m/z 223,
294 for MTD; m/z 224, 297 for MTD-d3; m/z 262, 277 for
EDDP; m/z 265, 280 for EDDP-d3; m/z 464, 677 for MOR;
m/z 467, 680 for MOR-d3; m/z 464, 523, 411 for 6-AM; m/z
467, 526, for 6-AM-d3.
Hair samples of neonates 2e2.5 cm in length reflect the
level of drug abuse of the mothers for 2e3 months before
delivery. The results revealed positive readings for MA,
MTD, EDDP, MOR, and COD at 865, 4145, 960, 180, and
180 pg/mg, respectively, for Case 1 (Figure 2A), and 1035,
15850, 1165, 1520, and 320 pg/mg, respectively, for Case 2
(Figure 2B). Figure 2C shows Case 3’s AP, MA, MTD, MOR,
COD, and 6-AM levels at 1115, 11396, 448, 3671, 1886, and
165 pg/mg, respectively.
4. Discussion
In the current study, we present neonatal case series whose
mothers had heroin addiction with methadone replacement
therapies during pregnancy for their clinical courses and
treatment outcomes. To our knowledge, this is the firstFigure 2 Gas chromatography/mass spectrometry-selected-
ion monitoring (GC/MS-SIM) chromatogram of the neonatal
hair of (A) Case 1, (B) Case 2, and (C) Case 3.report on this topic in East Asia.9 Two of the cases’ mothers
had no idea about using polydrug with amphetamine fois-
ted. Mild to moderate NAS was identified among these
cases, including moderate tremors when undisturbed, high-
pitched cry, irritability, tachypnea, poor feeding with
uncoordinated sucking for all of them, or even hyperto-
nicity and cerebral dysfunction by electroencephalography
for one case, which is similar to previous clinical reports.5e8
To a certain extent, findings on the scores of modified
Finnegan neonatal abstinence scoring system might be
a sign of the exposure levels and durations of heroin
addiction reported by subjects. Fortunately, other than
hepatitis C for one mother, the babies were born free of
bloodborne virus infections and sexually transmitted
diseases.3 Although all the cases were nearly full term
(34e38 weeks), IUGR, defined by low birth weight, was
observed in two cases (Table 1). Psychiatric comorbidity of
the mothers and unconscious polydrug use make the clinical
management even more challenging.8,9
Quantitative hair specimens can be used to draw
a gestational drug exposure profile and to study its poten-
tial link with the appearance of NAS. Nevertheless, the
amount of neonatal hair is often insufficient because case
mothers do not consent to infant hair collection for
cosmetic or specific cultural reasons. Although the neonate
hair sample is often small in amount, our modified assay
method using 10 mg still provided enough sensitivity
detection of the abused drugs, and gave applicable infor-
mation to trace the illegal drugs used during pregnancy.
The limit of detection and limit of quantification obtained
were 40 pg/mg for AP, MA, MDA, MDMA, and MTD and
80 pg/mg for K, NK, EDDP, MOR, COD, and 6-AM when only
10 mg of hair sample was used.20 Calibration curves for 10
analytes were established in the concentration range of
0.08e5 ng/mg with a correlation coefficient (r2) of 0.997,
using 200 pg/mg deuterated analogs of each analyte as
internal standards for quantification.20
In addition to patients’ self reports, drug testing
provides precise clinical information to assess individual
exposures to illicit drugs. Samples of urine and blood are
the most commonly used specimens, but their detection
windows are only the preceding few days. Only one case’s
urine sample (Case 3) was found with traceable opiate
because his mother used it 1 day before delivery. Because
illicit drugs and their metabolites can disappear from the
urine and the bloodstream within days, a neonatal hair
specimen would be a better alternative because of its
substantially wider detection window, enabling retrospec-
tive inspection of chronic exposure. In this study, we
found that the mothers of Cases 1 and 2 both had experi-
ences of methadone treatment programs because high
concentrations of methadone and EDDP were found in
neonatal hair. In addition, they also abused methamphet-
amine frequently. Moreover, the laboratory evidence
showed that the mother of Case 2 abused heroin habitually,
and Case 1 showed a low level of MOR and COD, indicating
that the mother had abstained from heroin. Compared to
Case 1, the higher levels of MTD and EDDP for Case 2 sug-
gested that it could be the case that the illicit drugs she
used contained methadone because she was only treated
with methadone for 1 week. The other minor but notice-
able issue was this case’s weakened liver function due to
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life period of methadone, which is 24e36 hours for healthy
people. Hair testing results of Case 3 showed that the
mother abused both heroin and methamphetamine, and she
had experienced fewer methadone treatments, shown by
the low amount of methadone in her hair. Although
amphetamine and/or methamphetamine was identified in
neonatal hair samples in the current study, we did not find
the related physical conditions or abnormal brain devel-
opment suggested in the literature among these babies.23,24
However, concerns about neurobehavioral development for
prenatal amphetamine exposure remain,25 and further
follow-up with intensive assessment is recommended. Drug
abuse in women of childbearing age is an emerging issue
worldwide.1,2 A better understanding on the clinical cour-
ses of subjects with polydrug use and experiences of
treatment are in demand. Thus, the development of
intensive prenatal care strategies and enrollment in treat-
ment programs before/after delivery are of interest for
future studies.
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